23:40:07 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


Cereno Scientific är verksamma inom bioteknik. Bolaget är specialiserade inom läkemedelsutveckling av vanliga och sällsynta kardiovaskulära sjukdomar. Den främsta läkemedelskandidaten utvecklas för behandling av den sällsynta sjukdomen pulmonell arteriell hypertension (PAH), samt för trombosindikationer. Särskilt används epigenetisk modulering för att utveckla behandlingar för behövande patienter med kardiovaskulära sjukdomar. Huvudkontoret ligger i Mölndal med kontor även i Nordamerika.


2023-05-17 Kvartalsrapport 2023-Q1
2023-02-22 Bokslutskommuniké 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-02 Ordinarie utdelning CRNO B 0.00 SEK
2022-06-01 Årsstämma 2022
2022-05-19 Kvartalsrapport 2022-Q1
2022-02-28 Extra Bolagsstämma 2022
2022-02-09 Bokslutskommuniké 2021
2021-11-16 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-10 Ordinarie utdelning CRNO B 0.00 SEK
2021-06-09 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-09-29 Extra Bolagsstämma 2020
2020-08-28 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning CRNO B 0.00 SEK
2020-06-10 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-30 Kvartalsrapport 2019-Q2
2019-08-28 Extra Bolagsstämma 2019
2019-06-19 Årsstämma 2019
2019-06-12 Ordinarie utdelning CRNO B 0.00 SEK
2019-05-23 Kvartalsrapport 2019-Q1
2019-02-22 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-06-14 Ordinarie utdelning CRNO B 0.00 SEK
2018-06-13 Årsstämma 2018
2018-05-24 Kvartalsrapport 2018-Q1
2018-04-19 Extra Bolagsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-11-14 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-06-22 Ordinarie utdelning CRNO B 0.00 SEK
2017-06-21 Årsstämma 2017
2017-05-24 Kvartalsrapport 2017-Q1
2017-02-22 Bokslutskommuniké 2016
2016-11-11 Kvartalsrapport 2016-Q3
2016-09-09 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2022-09-01 17:44:30

Cereno Scientific (XSAT: CRNO B) ("Cereno" or the "Company) today announced that it has been brought to the Company's attention that a block trade has been executed, where members of the Company's Board of Directors and management have sold warrants of series TO2 to an unnamed buyer. In connection with the transaction a subscription commitment for the exercise of warrants of series TO2 has been undertaken by the buyer.

The transaction involves 827,814 warrants of series TO2 and has been executed outside of the marketplace. The purpose of the transaction has been to allow for investors to acquire shares in the Company and to achieve the best possible subscription rate during the subscription period for the warrants of series TO2.

The subscription commitment involves all 827,814 warrants, of which 80,000 was taken over from a previous a subscription commitment made by the Board of Directors and management.

The subscription commitment has been agreed in writing and no consideration is to be paid for the subscription commitment. The subscription commitment is not secured through bank guarantees, restricted funds, pledged assets or similar arrangements.

Further information about the warrants of series TO2 can be found on the Company's website.

For further information, please contact:

Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com

About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1's safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist. In preclinical studies CS585 has been documented to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies CS014 has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Cereno Scientific is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.